Kura Oncology Inc. and Kyowa Kirin Co., Ltd. have formed a global strategic partnership to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor, aimed at treating patients with acute myeloid leukemia (AML) and other blood cancers.   According to the agreement, Kura will receive an upfront payment of $330 million and anticipates up to $420 million in near-term milestone payments, including a payment when ziftomenib is launched for monotherapy in relapsed/refractory ...